InflaRx (IFRX) Retained Earnings (2016 - 2026)
InflaRx (IFRX) posted Retained Earnings of -$448.9 million for Q1 2026, down 2.06% sequentially from -$439.8 million in Q4 2025, and down 25.33% YoY from -$601.1 million in Q1 2025.
InflaRx (IFRX) Retained Earnings (2016 - 2026) Analysis & Trends
InflaRx has reported Retained Earnings for 11 years, with the latest figure at -$448.9 million in Q1 2026.
- Quarterly Retained Earnings fell 25.33% year-over-year to -$448.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$448.9 million (down 25.33% YoY) and the FY2025 annual result came in at -$426.9 million, down 18.73% from the prior year.
- Retained Earnings declined to -$448.9 million in Q1 2026 per IFRX's latest filing, from -$439.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$237.4 million in Q3 2022 and troughed at -$448.9 million in Q1 2026.
- A 5-year average of -$329.0 million and a median of -$321.3 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings increased 0.01% in 2022, then declined 25.33% in 2026.
- Over 5 years, Retained Earnings stood at -$248.4 million in 2022, then decreased by 23.94% to -$307.9 million in 2023, then slipped by 15.31% to -$355.0 million in 2024, then retreated by 23.9% to -$439.8 million in 2025, then retreated by 2.06% to -$448.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$448.9 million, -$439.8 million, and -$429.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 4.38 Bn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Bn | -458.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448.89 Mn |
| Dec 31, 2025 | -439.81 Mn |
| Sep 30, 2025 | -429.26 Mn |
| Jun 30, 2025 | -401.76 Mn |
| Mar 31, 2025 | -358.17 Mn |
| Dec 31, 2024 | -354.98 Mn |
| Sep 30, 2024 | -359.21 Mn |
| Jun 30, 2024 | -333.44 Mn |
| Mar 31, 2024 | -321.33 Mn |
| Dec 31, 2023 | -307.86 Mn |
| Sep 30, 2023 | -294.13 Mn |
| Jun 30, 2023 | -286.11 Mn |
| Mar 31, 2023 | -273.21 Mn |
| Dec 31, 2022 | -248.39 Mn |
| Sep 30, 2022 | -237.38 Mn |
| Jun 30, 2022 | -242.77 Mn |
| Mar 31, 2022 | -255.87 Mn |
| Dec 31, 2021 | -244.78 Mn |
| Sep 30, 2021 | -237.40 Mn |
| Jun 30, 2021 | -227.91 Mn |